ImmunoPrecise Antibodies (TSXV:IPA; OTC:IPATF) has received a five-year subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the NCI, to discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.
The rabbit monoclonal antibodies discovered and produced under the subcontract will be used in the key applications of immunohistochemistry and immuno-multiple reaction monitoring (immuno-MRM). The antibodies will be generated for NCI’s antibody characterization program.
Immuno-MRM is a leading edge targeted mass spectrometry technique that relies on antibodies to enrich peptides from complex biological samples that are then quantified by mass spectrometry. Immuno-MRM is being used to discover novel biomarkers and develop a new generation of clinical diagnostic tests that could lead to improved cancer detection, diagnosis, and treatment.
IPA’s B-Cell Select platform enables rabbit monoclonal antibody discovery directly from B-cells through recombinant DNA cloning and expression of antibody gene sequences. This process allows for large panels of antibodies to be screened for functionality via multiple methods to pick the most relevant leads for the final application and can be applied to discover antibodies from several species for diagnostics and therapeutics.
“We look forward to applying IPA’s experience and expertise in developing rabbit monoclonal antibodies to the challenging projects being advanced through Leidos,” Deanna Dryhurst, CSO of IPA, said in a statement.
